Trial Profile
Comparison of the efficacy and safety of Latanoprost 0.005% (Xalatan Reference) and Latanoprost 0.005% (Sun Pharma Advanced Research Company Ltd) administered once daily in open angle glaucoma and ocular hypertension.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Latanoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 23 Apr 2015 New trial record